Pharvaris Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pharvaris (PHVS).

Price Target Range — 12 Quarters

Analyst Consensus — 14 Analysts

3S.Buy

10Buy

1Hold

Consensus RatingOverweight# Analysts14Avg. Consensus PT$46Upside to Avg. PT+28.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$51→$52
Aug 13, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$39→$40
Aug 13, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$74→$75
Jul 15, 2026	Wells Fargo	Yanan Zhu	Initiate	Overweight	$55
Jun 25, 2026	Morgan Stanley	Maxwell Skor	PT Raise	Overweight	$41→$46
May 13, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$75→$74
Apr 9, 2026	Wolfe Research	Andy Chen	Initiate	Outperform	$42
Apr 7, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$41→$42
Apr 6, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$52→$51
Mar 9, 2026	RBC Capital	Brian Abrahams	Initiate	Outperform	$52
Mar 3, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$60
Dec 4, 2025	Oppenheimer	Justin Kim	PT Raise	Outperform	$44→$50
Dec 4, 2025	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$32→$39
Dec 4, 2025	Morgan Stanley	Matthew Harrison	PT Raise	Overweight	$37→$41
Dec 4, 2025	B of A Securities	Tazeen Ahmad	PT Raise	Neutral	$27→$30
Dec 3, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$60
Nov 14, 2025	Morgan Stanley	Matthew Harrison	PT Raise	Overweight	$34→$37
Nov 13, 2025	Wedbush	Laura Chico	PT Raise	Outperform	$27→$30
Nov 13, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$60
Oct 15, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Initiate	Buy	$60

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $52

RBC Capital analyst Brian Abrahams maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $51 to $52.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $40

Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises the price target from $39 to $40.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $75

Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and raises the price target from $74 to $75.

Benzinga Newsdesk

PRO
Wells Fargo Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $55

Wells Fargo analyst Yanan Zhu initiates coverage on Pharvaris (NASDAQ:PHVS) with a Overweight rating and announces Price Target of $55.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $46

Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $41 to $46.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Pharvaris, Lowers Price Target to $74

Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and lowers the price target from $75 to $74.

Benzinga Newsdesk

Pharvaris NV

Pharvaris Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $52

PRO
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $40

PRO
Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $75

PRO
Wells Fargo Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $55

PRO
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $46

PRO
Citizens Maintains Market Outperform on Pharvaris, Lowers Price Target to $74

People Also Watch

People Also Watch

Benzinga

Benzinga

Pharvaris NV

Pharvaris Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $52

PROGuggenheim Maintains Buy on Pharvaris, Raises Price Target to $40

PROCitizens Maintains Market Outperform on Pharvaris, Raises Price Target to $75

PROWells Fargo Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $55

PROMorgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $46

PROCitizens Maintains Market Outperform on Pharvaris, Lowers Price Target to $74

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $52

PRO
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $40

PRO
Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $75

PRO
Wells Fargo Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $55

PRO
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $46

PRO
Citizens Maintains Market Outperform on Pharvaris, Lowers Price Target to $74